Klein Law Firm Announces February 8, 2022 Lead Plaintiff deadline in class action lawsuit filed on behalf of shareholders of Revance Therapeutics, Inc.


NEW YORK, NY / ACCESSWIRE / December 16, 2021 / Klein law firm announces that a class action lawsuit has been filed on behalf of shareholders of Revance Therapeutics, Inc. (NASDAQ: RVNC) alleging that the company violated federal securities laws.

Class period: November 25, 2019 at October 11, 2021

Lead Applicant Deadline: February 8, 2022

No obligation or cost to you.

Learn more about your recoverable losses in RVNC:

Revance Therapeutics, Inc. Loss Submission Form

Revance Therapeutics, Inc. NEWS – RVNC NEWS

CLASS ACTION CASE DETAILS: The complaint filed alleges that Revance Therapeutics, Inc. made materially false and / or misleading statements and / or failed to disclose that: (i) deficiencies in quality control existed at the DaxibotulinumtoxinA manufacturing plant for injection (“DXAI”) from the company; (ii) the aforementioned shortcomings reduced the likelihood that the Food and Drug Administration (“FDA”) would approve the DAXI Biologics (“BLA”) license application in its current form; (iii) as a result, it was unlikely that the DAXI BLA would obtain FDA approval within the time frame that the Company presented to investors; and (iv) accordingly, the Company’s public statements were materially false and misleading at all material times.

WHAT THIS MEANS FOR YOU AS A SHAREHOLDER: If you have suffered a loss at Revance, you have until February 8, 2022 apply to the court for principal applicant status. Your ability to participate in any recovery does not require you to serve as the lead applicant.

NO COT FOR YOU: If you purchased Revance securities during the relevant period, you may be entitled to compensation without payment of out-of-pocket expenses.

HOW TO PROTECT YOUR FINANCIAL INTERESTS: For more information on the RVNC trial, please contact J. Klein, Esq. by phone at 212-616-4899 or click on this link.


J. Klein, Esq. represents investors and participates in securities litigation involving financial fraud nationwide. Klein Law Firm is a litigation firm with experience in a wide range of areas including securities law, corporate finance and commercial litigation. Since 2011, our experienced lawyers have achieved superior results for our clients with a personalized approach. Lawyer advertising. Past results do not guarantee similar results.


J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th floor
New York, New York 10118
[email protected]
Telephone: (212) 616-4899
Fax: (347) 558-9665

THE SOURCE: Klein law firm

See the source version on accesswire.com:
https://www.accesswire.com/678134/RVNC-ALERT-The-Klein-Law-Firm-Announces-a-Lead-Plaintiff-Deadline-of-February-8-2022-in-the-Class-Action- Registered-in-the-name-of-Revance-Therapeutics-Inc-shareholders


About Author

Comments are closed.